
# Assessing changes in cell composition in single-cell data

Koen Van den Berge Joint work with Alemu Takele Assefa & Bie Verbist Johnson & Johnson Innovative Medicine September 27, 2024 Wiesbaden, Germany

Johnson & Johnson Innovative Medicine

# Relative abundance of M&M's




### **HEALTHY** condition:

One bag of M&M's, with 5 colors.

Each color equally abundant at 20%.

# Relative abundance of M&M's



### **HEALTHY** condition:


One bag of M&M's, with 5 colors.

Each color equally abundant at 20%.

### **DISEASED** condition:

Red M&M's increase in abundance (20% to 33%).

# Relative abundance of M&M's



### **HEALTHY** condition:

One bag of M&M's, with 5 colors.

Each color equally abundant at 20%.

### **DISEASED** condition:

Red M&M's increase in abundance (20% to 33%).

We're constrained to 100%, therefore other colors must decrease in relative abundance.


# A composition of single cell types


In single-cell RNA-seq data, the M&M colors are cell types.

The same principle applies: only relative information available (compositional data).

Starting from the single-cell gene expression count matrix:

1. Each single cell gets assigned a cell type label (M&M color), based on its gene expression.





# A composition of single cell types


In single-cell RNA-seq data, the M&M colors are cell types.

The same principle applies: only relative information available (compositional data).

Starting from the single-cell gene expression count matrix:

- 1. Each single cell gets assigned a cell type label (M&M color), based on its gene expression.
- 2. One sums the number of cells per patient sample to derive the cell abundance count matrix.





# Compositional data require custom statistical models

In compositional data, we still want to infer upon the latent absolute abundance (actual number of M&Ms in the bag). Two main avenues are possible:

- 1. Compositional statistical model (e.g., Dirichlet-Multinomial).
- 2. Compositional transformations (e.g., centered or additive log-ratio).

Let  $Y_{ip}$  denote the cell type counts for cell population p in sample i. The centered-log-ratio (CLR) transformation is

$$Z_{ip} = log\left[\frac{Y_{ip}}{\widetilde{Y_i}}\right] = log\left[\frac{Y_{ip}}{(\prod_i Y_{ip})^{1/P}}\right],$$

With  $\widetilde{Y}_i$  the geometric mean across cell types for sample i, and P the total number of cell populations.

# Compositional data require custom statistical models

In compositional data, we still want to infer upon the latent absolute abundance (actual number of M&Ms in the bag). Two main avenues are possible:

- 1. Compositional statistical model (e.g., Dirichlet-Multinomial).
- 2. Compositional transformations (e.g., centered or additive log-ratio).

In this talk, we will benchmark the most popular methods out there for assessing differential cell type composition.

Through identifying shortcomings of existing methods,

we develop new methodology by leveraging building blocks from other methods in the literature.

# An overview of existing methods

### **Compositional transformation**

- CLR\_lm
   Linear model post CLR
   transformation.
- LinDA
   Linear model post CLR
   transformation. Bias correction on effect size.

### Non-compositional transformation

- Limma-voom
   Log-counts-per-million transformation,
   weighted linear model and empirical
   Bayes shrinkage of residual variance.
- Propeller (logit and arcsin)

Linear model post logit or square root arcsine transformation.

### **Count model**

- edgeR
  - Negative binomial model, normalization of total count, empirical Bayes shrinkage of dispersion parameter.
- DESeq2

Negative binomial model, normalization of total count, empirical Bayes shrinkage of dispersion parameter.


NB GLM

Negative binomial model using total count as offset.

DCATS

Beta-Binomial model with shared dispersion parameter.

# Performances of existing methods



Alemu Takele Assefa

# Best performing method is still suboptimal


### Counts are still heteroscedastic post transformation

Let  $Y_{ip}$  denote the cell type counts for cell population p in sample i.


CLR: 
$$Z_{ip} = \log \frac{Y_{ip}}{\tilde{Y}_i}$$
 with  $\tilde{Y}_i = \left(\prod_{p=1}^P Y_{ip}\right)^{1/P}$ .

If 
$$Y_{ip} \sim Poi(\lambda_{ip})$$
,  $Var(Z_{ip}) = \left(\frac{P-1}{P}\right)^2 \frac{1}{\lambda_{ip}}$ .  
If  $Y_{ip} \sim NB(\mu_{ip}, \phi_p)$ ,  $Var(Z_{ip}) = \left(\frac{P-1}{P}\right)^2 \left(\frac{1}{\mu_{ip}} + \phi_p\right)$ .

Mean-variance relationship of counts (top row), and CLR-transformed counts (bottom row).




## Impact of accounting for heteroscedasticity





# Remember the M&M example; effect sizes are biased

Uncertainty in bias correction is not propagated in statistical inference



Modeling the fractions directly for each cell type independently would lead us to find all colors / cell types are changing.

We should only find the red color.

Effect sizes are biased due to compositionality.

# Best performing method is still suboptimal


Uncertainty in bias correction is not propagated in statistical inference

Method | Open access | Published: 14 April 2022

LinDA: linear models for differential abundance


LinDA: linear models for differential abundance analysis of microbiome compositional data

 $Var(\tilde{\beta}_{jp}) = Var(\beta_{jp}) + Var(\tilde{\beta}_{j}) - 2Cov(\beta_{jp}, \tilde{\beta}_{j}).$ 




# Impact of accounting for bias correction uncertainty

Bias correction uncertaintypropagation contributes to better false positive control





Alemu Takele Assefa


voomCLR is at least on par and often outperforms other



# Case study on breast cell atlas










https://doi.org/10.1038/s41588-024-01688-9

### A single-cell atlas enables mapping of homeostatic cellular shifts in the adult human breast



# Thank you



Alemu Takele Assefa



Bie Verbist

If you have more questions, please contact: kvande14@its.jnj.com

Johnson & Johnson Innovative Medicine